Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REN-1654
- Development stage
- Phase 2
- Lead developer
- Renovis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
REN-1654 is a small molecule drug that was developed as an inhibitor of tumor necrosis factor alpha (TNF-alpha) and p38 mitogen-activated protein kinase (p38 MAPK). It was investigated for its potential neuroprotective and anti-inflammatory effects in several indications, including neuropathic pain conditions such as post-herpetic neuralgia, sciatica, lumbosacral radiculopathy, cognitive impairment associated with AIDS dementia complex and other cognitive dysfunctions. The drug modulates the JNK signaling pathway and the MAPK/ERK signaling pathway. Despite reaching Phase 2 clinical trials for multiple indications, development of REN-1654 was discontinued after it failed to demonstrate significant efficacy in mid-stage studies[2][5][7][8].
- Other names
- Antineurodegeneratives, CentaurParkinsons therapy, Centaur
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))RK (Ribokinase)
Beyond the preview
Go deeper on REN-1654.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REN-1654.